Biotech Investing "Eleven clinical trials that will shape medicine in 2026" - BriaCell Phase 3 Trial Featured in Nature Medicine
Biotech Investing argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease
Biotech Investing BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025
Biotech Investing Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Biotech Investing Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Biotech Investing At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
Biotech Investing New Data from the Phase II ARCHER Trial Demonstrate CardiolRx Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions
Biotech Investing BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics
